JP2023071798A5 - - Google Patents

Download PDF

Info

Publication number
JP2023071798A5
JP2023071798A5 JP2023026852A JP2023026852A JP2023071798A5 JP 2023071798 A5 JP2023071798 A5 JP 2023071798A5 JP 2023026852 A JP2023026852 A JP 2023026852A JP 2023026852 A JP2023026852 A JP 2023026852A JP 2023071798 A5 JP2023071798 A5 JP 2023071798A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
aflibercept
intraocular
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023026852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023071798A (ja
JP7791125B2 (ja
Filing date
Publication date
Priority claimed from JP2020563409A external-priority patent/JP7235770B2/ja
Application filed filed Critical
Publication of JP2023071798A publication Critical patent/JP2023071798A/ja
Publication of JP2023071798A5 publication Critical patent/JP2023071798A5/ja
Application granted granted Critical
Publication of JP7791125B2 publication Critical patent/JP7791125B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023026852A 2018-05-10 2023-02-24 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤 Active JP7791125B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862669506P 2018-05-10 2018-05-10
US62/669,506 2018-05-10
US201862752127P 2018-10-29 2018-10-29
US62/752,127 2018-10-29
US201862769876P 2018-11-20 2018-11-20
US62/769,876 2018-11-20
US201962813882P 2019-03-05 2019-03-05
US62/813,882 2019-03-05
JP2020563409A JP7235770B2 (ja) 2018-05-10 2019-05-10 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
PCT/US2019/031879 WO2019217927A1 (en) 2018-05-10 2019-05-10 High concentration vegf receptor fusion protein containing formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020563409A Division JP7235770B2 (ja) 2018-05-10 2019-05-10 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤

Publications (3)

Publication Number Publication Date
JP2023071798A JP2023071798A (ja) 2023-05-23
JP2023071798A5 true JP2023071798A5 (enExample) 2023-11-07
JP7791125B2 JP7791125B2 (ja) 2025-12-23

Family

ID=

Similar Documents

Publication Publication Date Title
US11738064B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
Dumbrăveanu et al. A review of neovascular glaucoma. Etiopathogenesis and treatment
Pożarowska et al. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
JP6649393B2 (ja) Ｖｅｇｆおよびｐｄｇｆのリガンド結合ドメインを含む融合タンパク質
IL278375B2 (en) High concentration vegf receptor fusion protein containing formulations
RU2011113854A (ru) Способы ингибирования глазного ангиогенеза
CN103533950A (zh) Vegf拮抗剂在治疗血管生成眼病中的用途
Schlingemann et al. Treatment of retinal diseases with VEGF antagonists
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
FI4185318T3 (fi) Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
JP2023071798A5 (enExample)
Ichhpujani et al. Bevacizumab in glaucoma: a review
JPWO2022245739A5 (enExample)
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂
CN110327350B (zh) 多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
CA3149706A1 (en) Methods for treating ocular diseases
US20240199752A1 (en) Treatment of ophthalmic diseases
WO2025001907A1 (zh) 一种融合多肽aj007及其应用
US20230416351A1 (en) Vegf antagonist for use in methods for treating ocular diseases
Croasdell Association for Research in Vision and Ophthalmology (ARVO)-2018 Annual Meeting. Honolulu, Hawaii, USA-April 29-May 3, 2018
RU2024102531A (ru) Состав на основе раствора белка, содержащий антитело к vegf в высокой концентрации
Pandey Role of anti-vascular endothelial growth factor (VEGF) in ophthalmology
RU2020137402A (ru) Способы лечения заболевания с использованием забуференных составов бевацизумаба
Pecen et al. Future therapies